Related Experiment Video
Updated: Feb 26, 2026
Functional Assessment of the Donor Heart During Ex Situ Perfusion: Insights from Pressure-Volume Loops and Surface Echocardiography
Published on: October 11, 2022
Impact of Compound Hypertonic Saline Solution on Decompensated Heart Failure
Yanfang Wan1, Lei Li1, Heping Niu1
1Department of Cardiology, Cangzhou Central Hospital, Hebei Medical University.
Insights
Compound hypertonic saline solution (C-HSS) with furosemide significantly reduced hospitalization time, readmission rates, and mortality in heart failure patients. This treatment offers a promising approach for managing decompensated heart failure (NYHA class III).
Area of Science:
- Cardiology
- Nephrology
- Internal Medicine
Background:
- Heart failure (HF) management, particularly for New York Heart Association (NYHA) class III patients, presents significant challenges in reducing hospitalizations and mortality.
- Optimizing diuretic therapy and fluid management is crucial for improving outcomes in decompensated heart failure.
Purpose of the Study:
- To investigate the efficacy of compound hypertonic saline solution (C-HSS) combined with high-dose furosemide in managing NYHA class III heart failure.
- To evaluate the impact of C-HSS on hospitalization duration, readmission frequency, and patient mortality.
Main Methods:
- A randomized open-label study involving 264 NYHA class III heart failure patients with ejection fraction < 40%.
- Group 1 received furosemide (100 mg IV infusion) plus C-HSS (100 mL) twice daily with severe water restriction (500 mL/day).
- Group 2 received furosemide (100 mg IV bolus) twice daily with water restriction (500 mL/day), without C-HSS. Both groups maintained normal sodium intake (120 mmol/day).
Main Results:
- The C-HSS group exhibited increased urination, significantly reduced hospitalization time (4 ± 2 vs. 7 ± 2 days, P < 0.01), and lower hospitalization costs (2210 vs. 3506 RMB, P < 0.01).
- Over a 36 ± 12 month follow-up, the C-HSS group showed a significantly longer average readmission time (31.84 ± 7.58 vs. 15.60 ± 6.25 months, P < 0.01).
- Mortality rates were significantly lower in the C-HSS group (16.5% vs. 31.9%, P < 0.01).
Conclusions:
- Periodical administration of C-HSS, alongside strict water restriction and a normal sodium diet, is effective in reducing hospitalization duration in NYHA class III heart failure.
- This therapeutic strategy significantly decreases readmission rates and lowers mortality in patients with decompensated heart failure.
- C-HSS represents a valuable adjunct therapy for improving long-term outcomes in heart failure management.
Abstract:
The aim of the present study was to evaluate the effects of hypertonic saline solution (C-HSS) with high dose furosemide on hospitalization time, readmission, and mortality in patients with New York Heart Association (NYHA) class III heart failure.Decompensated heart failure patients (NYHA III) with chronic ischemic or nonischemic cardiomyopathy and ejection fraction < 40% were divided into 2 groups in an open-label random manner: the first group received a 1-hour intravenous infusion of furosemide (100 mg) plus compound C-HSS (100 mL) twice daily and underwent serious water restriction (500 mL/day); the second group received furosemide intravenous bolus (100 mg) twice a day and water restriction (500 mL/day), without C-HSS. Both groups had normal sodium (120 mmol sodium) intake. After discharge, the two groups continued to receive 120 mmol Na/day and 500-1000 mL water/day.The first group (132 C-HSS patients) had an increase in urination, a reduction in hospitalization time (4 ± 2 versus 7 ± 2 days, P < 0.01), and a reduction in hospitalization costs (2210 RMB versus 3506 RMB, P < 0.01) compared with the second group (132 without C-HSS patients). During the follow-up period (36 ± 12 months), the first group had a significantly higher average readmission time (31.84 ± 7.58 months versus 15.60 ± 6.25 months, P < 0.01) and lower mortality rate (16.5% versus 31.9%, P < 0.01).The results suggest that periodical C-HSS administration, combined with serious water restriction and a normal sodium diet, significantly reduces the hospitalization time, readmission rate, and mortality in patients with NYHA class III HF.
Related Concept Videos
01:22Heart Failure Drugs: Diuretics
01:30Heart Failure V: Medical Management
01:29Heart Failure II: Pathophysiology
01:22Heart Failure VI: Adjunct Therapies
01:26Heart Failure Drugs: Inotropic Agents
01:17Pathophysiology of Heart Failure